Literature DB >> 10789738

Molecular prognostic factors in rectal cancer treated by radiation and surgery.

H Qiu1, P Sirivongs, M Rothenberger, D A Rothenberger, J Garciá-Aguilar.   

Abstract

PURPOSE: The aim of this study was to determine the biologic significance of tumor response and the prognostic value of molecular markers in a group of patients with rectal cancer treated with preoperative radiation therapy and radical surgery.
METHODS: Microsatellite instability, microvessel count, and immunohistochemistry for proliferating cell nuclear antigen, p53, p21, bcl-2, and vascular endothelial growth factor were performed in the preradiation biopsy specimen of 72 patients with rectal cancer treated by preoperative radiation therapy and radical curative surgery. Preoperative tumor stage by endorectal ultrasound was compared with pathology stage of the resected specimen. Mean follow-up was 50 months.
RESULTS: Twenty-eight patients (39 percent) responded to radiation therapy. The response was complete in 8 (12 percent) and partial in 20 patients (27 percent). Tumors with positive nodes in the surgical specimen were less likely to have responded to preoperative radiation (P = 0.03). Only p21 expression was individually associated with response to radiation (56 vs. 30 percent; P = 0.03). Tumors that were p53-negative/p21-positive or p21-positive/bcl-2-positive were also more likely to respond to radiation (83 vs. 35 percent; P = 0.03 and 71 vs. 31 percent; P = 0.01, respectively). The tumor relapsed in 21 patients (29 percent): locally in 7 (10 percent) and distally in 14 (19 percent). Recurrence was associated with lack of response to radiation, female gender, distal tumor location, high proliferating cell nuclear antigen labeling index, and low microvessel count. Probability of survival was greater for patients with well or moderately differentiated tumors and tumors that responded completely to radiation.
CONCLUSIONS: Tumor response to radiation is associated with improved tumor control and overall survival rate, and p21 expression is a marker of tumor radiosensitivity in patients with rectal cancer. Furthermore, a high proliferating cell nuclear antigen labeling index and a low microvessel count in the preradiation biopsy specimen may be prognostic indicators for tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10789738     DOI: 10.1007/bf02237186

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  18 in total

Review 1.  Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer.

Authors:  Zeeshan Ramzan; Ammar B Nassri; Sergio Huerta
Journal:  World J Gastrointest Oncol       Date:  2014-07-15

2.  Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.

Authors:  B Michael Ghadimi; Marian Grade; Michael J Difilippantonio; Sudhir Varma; Richard Simon; Cristina Montagna; Laszlo Füzesi; Claus Langer; Heinz Becker; Torsten Liersch; Thomas Ried
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

3.  p27 expression in post-treatment rectal cancer: a potential novel approach for predicting residual nodal disease.

Authors:  Tobias Leibold; Vanessa W Hui; Jinru Shia; Jeannine A Ruby; Elyn R Riedel; José G Guillem
Journal:  Am J Surg       Date:  2014-04-13       Impact factor: 2.565

4.  Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy.

Authors:  Marian Grade; Jochen Gaedcke; Danny Wangsa; Sudhir Varma; Jaje Beckmann; Torsten Liersch; Clemens Hess; Heinz Becker; Michael J Difilippantonio; Thomas Ried; B Michael Ghadimi
Journal:  Cancer Genet Cytogenet       Date:  2009-08

5.  Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Cem Terzi; Aras Emre Canda; Ozgul Sagol; Koray Atila; Devrim Sonmez; Mehmet Fuzun; Ilknur B Gorken; Ilhan Oztop; Funda Obuz
Journal:  Int J Colorectal Dis       Date:  2007-09-06       Impact factor: 2.571

6.  A study into methodology and application of quantification of tumour vasculature in rectal cancer.

Authors:  Femke Vlems; Erik van der Worp; Jeroen van der Laak; Cornelis van de Velde; Iris Nagtegaal; Han van Krieken
Journal:  Virchows Arch       Date:  2004-05-28       Impact factor: 4.064

Review 7.  Advances in the management of rectal cancer.

Authors:  D Lawes; P B Boulos
Journal:  J R Soc Med       Date:  2002-12       Impact factor: 18.000

8.  APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.

Authors:  Russell D Petty; Leslie M Samuel; Graeme I Murray; Graham MacDonald; Terrence O'Kelly; Malcolm Loudon; Norman Binnie; Emad Aly; Aileen McKinlay; Weiguang Wang; Fiona Gilbert; Scot Semple; Elaina S R Collie-Duguid
Journal:  BMC Cancer       Date:  2009-12-11       Impact factor: 4.430

9.  Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.

Authors:  Andrea Cercek; Gustavo Dos Santos Fernandes; Campbell S Roxburgh; Karuna Ganesh; Shu Ng; Francisco Sanchez-Vega; Rona Yaeger; Neil H Segal; Diane L Reidy-Lagunes; Anna M Varghese; Arnold Markowitz; Chao Wu; Bryan Szeglin; Charles-Etienne Gabriel Sauvé; Erin Salo-Mullen; Christina Tran; Zalak Patel; Asha Krishnan; Kaitlyn Tkachuk; Garrett M Nash; Jose Guillem; Philip B Paty; Jinru Shia; Nikolaus Schultz; Julio Garcia-Aguilar; Luis A Diaz; Karyn Goodman; Leonard B Saltz; Martin R Weiser; J Joshua Smith; Zsofia K Stadler
Journal:  Clin Cancer Res       Date:  2020-03-06       Impact factor: 12.531

10.  Clinical impact of HLA class I expression in rectal cancer.

Authors:  Frank M Speetjens; Elza C de Bruin; Hans Morreau; Eliane C M Zeestraten; Hein Putter; J Han van Krieken; Maaike M van Buren; Monique van Velzen; N Geeske Dekker-Ensink; Cornelis J H van de Velde; Peter J K Kuppen
Journal:  Cancer Immunol Immunother       Date:  2007-09-15       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.